Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.480 +0.130 (+2.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,280,160
Open 4.560
Bid (Size) 4.450 (1,000)
Ask (Size) 4.560 (200)
Prev. Close 4.350
Today's Range 4.430 - 4.750
52wk Range 2.940 - 5.100
Shares Outstanding 99,161,234
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire

Performance

YTD
-6.1%
-6.1%
1 Month
+2.8%
+2.8%
3 Month
-6.3%
-6.3%
6 Month
+0.2%
+0.2%
1 Year
+41.8%
+41.8%

More News

Read More
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
Via Stocktwits
Topics Intellectual Property
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
Via Stocktwits
Topics Intellectual Property
News headline image
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
From Roivant Sciences
Via GlobeNewswire
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗
Via Chartmill
News headline image
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus (ABUS) Q2 Revenue Surges 529% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
From Arbutus Biopharma Corporation
Via GlobeNewswire

Frequently Asked Questions

Is Arbutus Biopharma Corporation - Common Stock publicly traded?
Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.
What exchange does Arbutus Biopharma Corporation - Common Stock trade on?
Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?
The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market
What is the current price of Arbutus Biopharma Corporation - Common Stock?
The current price of Arbutus Biopharma Corporation - Common Stock is 4.480
When was Arbutus Biopharma Corporation - Common Stock last traded?
The last trade of Arbutus Biopharma Corporation - Common Stock was at 04/15/26 04:00 PM ET
What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?
The market capitalization of Arbutus Biopharma Corporation - Common Stock is 444.24M
How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?
Arbutus Biopharma Corporation - Common Stock has 444M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.